Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeurogesX has concluded patient recruitment in a Phase 2 clinical trial evaluating NGX-1998 in patients suffering from postherpetic neuralgia (PHN).
Subscribe to our email newsletter
NeurogesX has recruited around 183 patients for this trial.
The Phase 2 clinical study design included two stages.
The first stage was intended to establish the shortest tolerable anesthetic pretreatment regimen.
Whereas, the second stage was designed to investigate two NGX-1998 dose concentrations using the pretreatment regimens determined during stage 1.
The objective of the second stage is to select the appropriate concentration of NGX-1998 for further evaluation in a Phase 3 clinical program.
The company expects to release the top-line data from the study by the end of this year.
NeurogesX Research and Development executive vice president and CMO Jeffrey Tobias said with the completion of enrollment in their Phase 2 study, they are pleased to report another milestone in the development of NGX-1998, our liquid formulation of capsaicin.
"We are excited by the potential of NGX-1998 as it may be able to provide the benefits of high-concentration capsaicin in a rapid and convenient dosage form that should allow easy use by a broad range of healthcare providers," Tobias said.